Optimum peripheral drug deposition in patients with cystic fibrosis

被引:34
作者
Brand, P
Meyer, T
Häussermann, S
Schulte, M
Scheuch, G
Bernhard, T
Sommerauer, B
Weber, N
Griese, M
机构
[1] Inamed GmbH, D-82131 Gauting, Germany
[2] Bayer Healthcare LLC, Biol Prod, Res Triangle Pk, NC USA
[3] Asklepios Fachklin, Gauting, Germany
[4] Kinderklin Haunerschen Kinderspital, Munich, Germany
来源
JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG | 2005年 / 18卷 / 01期
关键词
alveolar deposition; cystic fibrosis; breathing pattern; particle size;
D O I
10.1089/jam.2005.18.45
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
In order to identify the optimum particle size and breathing pattern for high peripheral deposition of inhaled drugs in patients with cystic fibrosis, regional deposition in these patients was studied systematically as a function of particle size, inhalation volume and flow rate. Regional deposition was assessed using the single-breath regional deposition technique in which the concentration profile of inhaled and exhaled non-radioactive, monodisperse test particles is analyzed. Using this technique particle deposition within the functional dead space volume and peripherally can be assessed. Regional deposition was measured in 12 patients with cystic fibrosis using 2, 3, 4, and 5.5 mu m particles, inhalation volumes of 500, 1000, 1500, and 2000 cm(3), and inhalation flow rates of 100, 250, 500, and 750 cm(3)/sec. Peripheral deposition was highest when 2-3-mu m particles were inhaled with air-flow rates of 250-500 cm(3)/sec. With these parameters peripheral deposition increased with increasing inhalation volume and reached values of about 60% of the total drug inhaled. It has been shown that high peripheral drug deposition can be achieved in patients with CF when inhalations are performed using an optimized combination of particle size and breathing pattern.
引用
收藏
页码:45 / 54
页数:10
相关论文
共 29 条
  • [1] PULMONARY DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS
    ADJEI, A
    GUPTA, P
    [J]. JOURNAL OF CONTROLLED RELEASE, 1994, 29 (03) : 361 - 373
  • [2] AEROSOLS AS DIAGNOSTIC-TOOLS
    ANDERSON, PJ
    DOLOVICH, MB
    [J]. JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 1994, 7 (01): : 77 - 88
  • [3] [Anonymous], 1994, Ann ICRP, V24, P1
  • [4] Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis
    Barker, AF
    Couch, L
    Fiel, SB
    Gotfried, MH
    Ilowite, J
    Meyer, KC
    O'Donnell, A
    Sahn, SA
    Smith, LJ
    Stewart, JO
    Abuan, T
    Tully, H
    Van Dalfsen, J
    Wells, CD
    Quan, J
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (02) : 481 - 485
  • [5] Bonsignore C L, 1998, Pediatr Nurs, V24, P258
  • [6] Peripheral deposition of α-protease inhibitor using commercial inhalation devices
    Brand, P
    Beckmann, H
    Enriquez, MM
    Meyer, T
    Müllinger, B
    Sommerer, K
    Weber, N
    Weuthen, T
    Scheuch, G
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (02) : 263 - 267
  • [7] Intrapulmonary distribution of deposited particles
    Brand, P
    Häussinger, K
    Meyer, T
    Scheuch, G
    Schulz, H
    Selzer, T
    Heyder, J
    [J]. JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 1999, 12 (04): : 275 - 284
  • [8] Alveolar deposition of monodisperse aerosol particles in the lung of patients with chronic obstructive pulmonary disease
    Brand, P
    Meyer, T
    Sommerer, K
    Weber, N
    Scheuch, G
    [J]. EXPERIMENTAL LUNG RESEARCH, 2002, 28 (01) : 39 - 54
  • [9] Brand P, 2000, J PHARM SCI-US, V89, P724, DOI 10.1002/(SICI)1520-6017(200006)89:6<724::AID-JPS3>3.0.CO
  • [10] 2-B